AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug

cafead

Administrator
Staff member
  • cafead   Sep 29, 2021 at 11:22: AM
via AbbVie has landed an approval for Qulipta, the oral CGRP receptor antagonist it obtained via the $63 billion buyout of Allergan and the third FDA-approved drug in its migraine portfolio.

article source
 

<